打开APP

Actavis PK Sanofi !谁能赢得Omega的芳心?

  1. Actavis
  2. Omega
  3. 兼并
  4. 收购
  5. 非处方药

来源:生物谷 2014-10-23 15:45

最近有消息称,著名生物医药公司Actavis公司有意报价收购Omega生物医药公司。

2014年10月22日讯 /生物谷BIOON/ --最近有消息称,著名生物医药公司Actavis公司有意报价收购Omega生物医药公司。此前赛诺菲、勃林格殷格翰公司等生物医药巨头都有意收购Omega。而Actavis公司的加入无疑使这一竞争更趋白热化。

Omega生物医药公司主要致力于非处方药物的生产和销售。2013年公司的销售总额达到了15.5亿美元,高于2012年的13.3亿美元。而2014年财政年度的前半年,公司的销售额已经达到了15亿美元。而2013年Omega公司的净利润达到8千9百万美元,比2012年(8480万美元)增长了5.4%左右。目前公司经营的非处方药物涵盖了皮肤病、感冒、止痛药等多个领域,其畅销药物包括Solpadeine和Optalidon等。

Omerga公司于今年七月份表示计划出售公司业务,这也吸引了包括赛诺菲在内的数家生物医药巨头的注意。分析人士预计,Omerga公司的最终收购案价格将可能高达50亿美元左右。按照计划,所有有意收购Omega公司的买家都将于2014年11月提出自己的收购方案。

另一方面,Actavis公司也并非收购市场上的新手,早些时候公司也曾参与Salix Pharmaceuticals公司的收购案,后者最终被Allergan公司以108亿美元的价格获得。去年,Actavis公司收购了丹麦的Warner Chilcott Plc公司,帮助公司将税率由37%降至17%左右。而Actavis公司此次希望收购Omerga公司的目的在于增加公司业务的多样性,以进一步提升公司的竞争力。不过,有道是螳螂捕蝉黄雀在后。Actavis公司较低的税率也吸引了辉瑞公司的目光,最近有报道称辉瑞公司正在与Actavis公司接触,希望收购Actavis公司。(生物谷Bioon.com)

详细英文报道:

Actavis plc (ACT) has joined the list of suitors, along with Sanofi SA (ADR) (SNY), Boehringer Ingelheim GmbH, and Perrigo Company plc (PRGO), to acquire Omega Pharma NV, a private company that focuses on over-the-counter (OTC) drugs. The deal could be worth as much as €4 billion ($5 billion), Bloomberg reported early Tuesday morning.

People familiar with the matter said that Actavis is pursuing Omega and is one of the final bidders. The sources have chosen to remain anonymous because the information is private.

Actavis, along with other bidders, will be supplying Omega with a final offer next month, while all bidders continue to evaluate Omega's potential and perform other necessary measures.

Omega, headquartered in Nazareth, Belgium, is a specialty pharmaceutical and a leading player in the OTC drug market. The company traded on the Euronext Brussels stock exchange for 13 years until February 2012, when it was privatized by its founder Marc Coucke's company Alychlo NV and another company, Waterland Private Equity Fund, for €848 million ($1.08 billion). At the time, the company had market capitalization of €754 million ($966 million).

Omega generated sales of €1.21 billion ($1.55 billion) in 2013, higher when compared to €1.04 billion ($1.33 billion) generated in 2012. According to some sources, the company has already accumulated €1.2 billion ($1.5 billion) in revenue during the first half of the current year.

The company said that its earnings before interest, taxes, depreciation, and amortization (EBITDA) for 2013 amounted to €231 million ($296.4 million), up 14.1% when compared to earnings generated in 2012. Net income for 2013 amounted to €69.6 million ($89.2 million), up 5.1% from €66.2 million ($84.8 million) in 2012. As per the company's website, assets were reported at €2.18 billion ($2.79 billion) on the balance sheet.

Omega has nearly 2,000 brands which cover dermatological, cough & cold, anti-parasites, pain-relief, and other OTC drugs. These include some highly sold OTC drugs such as Solpadeine and Optalidon.

Reports had surfaced in July this year that Omega is looking for a suitor to sell off its business. The news was confirmed when it was found that Morgan Stanley (MS) is advising the company in this regard. Later, Boehringer and Perrigo emerged as among the interested companies. In August, Sanofi and Bayer AG (ADR) (BAYRY) were also said to be in talks with Omega.

Actavis' Pursuit Of Acquisition Targets

Omega is not the first company that Actavis is looking to acquire. Earlier, there was news that Actavis had approached Salix Pharmaceuticals, Ltd. (SLXP) with an acquisition offer. Salix, valued at $10.8 billion, was earlier being pursued by Allergan, Inc. (AGN), which itself is looking to acquire a company to make itself a complex and expensive acquisition target for Valeant Pharmaceuticals Intl Inc (VRX). Allergan is reported to have dismissed the idea of acquiring Salix on valuation concerns and shareholder pressure.

Actavis currently has market capitalization of $59.4 billion after yesterday's 2% gain in share price on the news. The company seems to be working to expand its business aggressively. It closed a merger dealwith Durata Therapeutics Inc (DRTX) this month to bring into its fold Durata's infectious disease portfolio, mainly comprising injectable antibiotic Dalvance for treatment of skin infections. The acquisition was valued at $675 million, where Actavis will pay $23 in cash for each share of Durata. The merger is expected to be completed by early next year.

Last year, Actavis acquired Ireland-based Warner Chilcott Plc - a move that enabled Actavis to shift its corporate headquarters from New Jersey to Dublin. The tax-inversion deal, valued at $5 billion, helped Actavis lower its effective tax rate to nearly 17%, compared to the earlier 37% before the deal. These tax-inversion deals enable companies to free their foreign cash flows, which would otherwise be taxed heavily. Actavis certainly seems to be making use of the tax savings by putting the money into acquisitions.

However, an Irish-based domicile has also made Actavis an acquisition target for Pfizer Inc. (PFE), which is looking to acquire a company for tax-inversion purposes.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->